报价延迟最少15分钟:2026/06/21 09:53 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
21.96 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-0.65/--
|
|
企业价值
1.44B
|
| 资产负债 |
|
每股账面净值
-2.57
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
74.21M
|
|
每股收益
--
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Alamar Biosciences Inc is a proteomics company engaged in protein detection and analysis. The company has developed its own NULISA (NUcleic Acid Linked Immuno-Sandwich Assay) technology as the foundation of its Precision Proteomics platform enabling the detection and quantification of protein biomarkers in a single sample with ultra-high sensitivity and high specificity, even from very small volumes of biofluid. The company operates in single segment and focuses on developing a good sensitive proteomic liquid biopsy platform and sells instruments, consumables, and services based on this platform to enable early detection of diseases. The products of the company includes NULISAseq Panels, NULISAqpcr Assays, and others. |
